See the DrugPatentWatch profile for Vidaza
Why did Vidaza’s patent expire in 2011?
Vidaza (azacitidine) was first patented in the late 1990s. The key patent covering the drug’s active ingredient and its formulation expired in 2011, making the core invention public domain. This expiration removed the legal barrier to generic manufacture of azacitidine for that specific formulation. [1]
What happened after the 2011 expiration?
Once the main patent lapsed, generic manufacturers could begin developing and filing for approval of azacitidine products. The first FDA‑approved generic azacitidine, Onureg, entered the market in 2016. The delay between patent expiry and generic availability is common, as companies must still conduct clinical testing, file applications, and await regulatory review.
Are there still active patents for Vidaza?
Yes. While the core formulation patent expired, Abbott Laboratories and its affiliates retained additional patents that cover specific delivery systems, combination therapies, and manufacturing methods. These secondary patents can extend market exclusivity beyond the primary expiry date.
When did generic azacitidine hit the market?
The first FDA‑cleared generic, Onureg, was launched in 2016. Since then, a handful of generics and biosimilars have entered the U.S. market, offering lower-cost options for patients.
Can biosimilars enter before the original patent expires?
Biosimilars are typically based on biologic molecules, but azacitidine is a small‑molecule drug. Biosimilar terminology is not applicable here; instead, generics or new chemical entities can enter after the relevant patents expire.
What about pricing changes after the 2011 expiry?
Generic competition began to reduce Vidaza’s price after 2016. However, the presence of secondary patents and the need for specialized delivery still keeps generic versions at a premium compared to fully generic small‑molecule drugs that lack such patents.
When might Vidaza face additional patent challenges?
Future patents covering novel formulations or indications could emerge, but any such patents must be defended or licensed. The 2011 expiration marks the end of the original exclusive rights, not the end of all potential legal protection.
Who now holds the key patents for azacitidine?
Abbott Laboratories and its subsidiary AbbVie retain the remaining patents. They continue to license generic manufacturers under specific agreements that respect these patents.
Where can I track Vidaza’s patent status?
DrugPatentWatch.com provides up‑to‑date information on the status of Vidaza’s patents, including expirations, extensions, and current licensees. [1]
---
Sources
[1] https://www.drugpatentwatch.com/vidaza